RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.64

Change

+0.27 (+2.19)%

Market Cap

N/A

Volume

6.70K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.08 (+0.18%)

USD 1.42B
PSQ ProShares Short QQQ

+0.04 (+0.10%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

+0.10 (+0.45%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

-0.50 (-3.03%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+0.49 (+1.30%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

+0.58 (+1.15%)

USD 0.23B
RWM ProShares Short Russell2000

+0.04 (+0.20%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

+0.20 (+1.88%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

+0.01 (+0.09%)

USD 0.18B
DOG ProShares Short Dow30

+0.12 (+0.44%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.22% 85% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.22% 85% B 81% B-
Trailing 12 Months  
Capital Gain 15.68% 96% N/A 84% B
Dividend Return 2.67% 60% D- 50% F
Total Return 18.35% 96% N/A 85% B
Trailing 5 Years  
Capital Gain -54.84% 80% B- 7% C-
Dividend Return 3.13% 74% C 6% D-
Total Return -51.71% 80% B- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 66.86% 39% F 96% N/A
Dividend Return 68.32% 39% F 96% N/A
Total Return 1.47% 60% D- 35% F
Risk Return Profile  
Volatility (Standard Deviation) 432.96% 63% D 3% F
Risk Adjusted Return 15.78% 52% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.